Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8246 participants.
Also called NCT01986881
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 8,246 participants
- Sponsor
- Registry
-
NCT01986881 -
2013-002518-11
-
- Other papers using this trial's data
- Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
- Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
- Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
- Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial
- Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
- Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
- Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
- The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01986881. Randomized; double masking; primary purpose treatment. Start 2013-11-04 (actual); primary completion 2019-12-27 (actual). Results posted on 2021-02-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Glycemic Rescue
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct01986881- Content hash
c43bef21540a5d092343982a4d684634d4fad01e4b8d5c7a9d86033a484b1676